Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 8/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210984 | 0.82 | GRIN1 (0.36) | GRIN1GRIN2BFGFR1 | |
| SCHEMBL23210847 | 0.78 | GRIN1 (0.40) | GRIN1GRIN2BGABRA1GABRG2GABRB3 | |
| SCHEMBL23236599 | 0.77 | GRIN1 (0.33) | GRIN1GRIN2B | |
| SCHEMBL23210732 | 0.76 | GRIN1 (0.34) | GRIN1GRIN2BGABRA1GABRG2GABRB3 | |
| SCHEMBL23210941 | 0.76 | ACSS2 (0.43) | GRIN1GRIN2BMEN1MAPTKMT2A | |
| SCHEMBL23210813 | 0.75 | GRIN1 (0.38) | GRIN1GRIN2B | |
| SCHEMBL23901367 | 0.74 | HDAC8 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL25364430 | 0.74 | RAB9A (0.34) | HSD17B10RAB9AKMT2A | |
| SCHEMBL23211138 | 0.72 | MAPK1 (0.32) | DYRK1ADYRK1BPLK4AURKAJAK2 | |
| SCHEMBL19949831 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-09-10 | — | — | US | disclosed |
| CN-111295384-A | Bicyclic derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | disclosed |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | disclosed |
| WO-2018049214-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | GRIN1 2482/4885GRIN2B 3536/4885GABRA1 4487/4885 |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885GABRA1 776/4885 |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885GABRA1 776/4885 |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | GRIN1 2482/4885GRIN2B 3536/4885GABRA1 4487/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885GABRA1 776/4885 |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | GRIN1 2482/4885GRIN2B 3536/4885GABRA1 4487/4885 |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | GRIN1 2482/4885GRIN2B 3536/4885GABRA1 4487/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885GABRA1 776/4885 |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | GRIN1 2482/4885GRIN2B 3536/4885GABRA1 4487/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRIN1 2634/4885GRIN2B 2843/4885GABRA1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.